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LincRNA-Y MODULATES OSTEOGENIC DIFFERENTIATION VIA Wnt/b-CATENIN
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Objective: Bone homeostasis is tightly orchestrated and maintained by the bal-
ance between osteoblasts and osteoclasts. Recent studies have broad our knowl-
edge of long non-coding RNAs (lncRNAs) in bone metabolism and more and more
emerging evidences have demonstrated that some lncRNAs play important regu-
latory roles in osteoblast differentiation of MSCs, suggesting a potential thera-
peutic strategy for bone formation. As a newly discovered large intergenic
non-coding RNA, lincRNA-Y was reported to mediate the reprogramming of hu-
man pluripotent stem cells. It was also found that this lincRNA induced epithe-
lial-to-mesenchymal transition and contributed to tumorigenesis and metastasis.
However, little is known about the role of lincRNA-Y in the osteoblast differen-
tiation of MSCs. Therefore, the aim of our study is to investigate the function of
lincRNA-Y in osteogenic differentiation and try to elucidate the the underlying
mechanisms.
Methods: Human mesenchymal stem cells (hMSCs) were isolated and cultured ac-
cording to our previous studies. The osteogenic differentiation of hMSCs was eval-
uated by ALP activity, ARS staining and marker genes expression. The lincRNA-Y
overexrepssion vector was constructed and stably transfected into hMSCs to study
its function in osteogenic differentiation. To identify which miRNAs directly target
lincRNA-Y, the bioinformatic investigations was performed and the luciferase re-
porter assay was conducted for further confirmation.
Results: In the present study, lincRNA-Y was found to be upregulated during oste-
ogenic differentiation in hMSCs. Further evidence showed that its overexpression
promoted while its knockdown suppressed osteoblast differentiation. Interest-
ingly, the lincROR has been identified as a ceRNA or miRNA sponge to regulate
the transcriptional factors Oct4, Sox2 and Nanog in human ESCs. According to
the prediction, lincRNA-Y functioned as a natural miRNA decoy for miR-138 and
miR-145, which all suppressed osteogenic differentiation. The further investiga-
tion also showed the lincRNA-Y promoted b-catenin expression, suggesting acti-
vating Wnt/b-catenin pathway.
Conclusion: Taken together, these findings indicate that lincRNA-Y significantly
promoted osteogenic differentiation by serving as a ceRNA for miRNAs, which indi-
cated that it might help to develop a potential therapeutic target for bone
fracture.
http://dx.doi.org/10.1016/j.jot.2016.06.070330
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Objective: Our previous research showed that low dose X-irradiation (LDI) can pro-
mote callus mineralisation, and stimulate osteoblasts proliferation and function. In
this study we focused on the relationship of LDI and osteoclasts and the potential
mechanism.
Methods: Osteoclasts were randomized into an LDI group (cells exposed to irra-
diation of 100 mGy), a P2X7/- LDI group(LDI group with P2X7 receptor
defected), and a SHAM group (cells exposed to 0mGy). The concentration of
ATP in the supernatant was detected by an immunofluorescence staining kit. A
TRAP staining method was employed to examine the differentiation of osteo-
clasts. The expression of P2X7 receptor and Cathepsin-K genes’ mRNA in osteo-
clasts were evaluated by quantitative real-time polymerase chain reaction (Q-
PCR).
Results: The releasing of ATP was significantly improved in the LDI group and the
P2X7/ LDI group, with more in the LDI group. TRAP staining showed that LDI
enhanced osteoclasts differentiation and maturity. The expression of P2X7 recep-
tor and Cathepsin-K genes’ mRNA increased in the LDI group compared to the
P2X7/ LDI group, and the SHAM group, while the expression of Cathepsin-K
declined in the P2X7/ LDI group.
Conclusion: LDI promoted differentiation and function of osteoclasts by releasing
ATP and activating the P2X7 receptor.
Funding/support: This study was sponsored by a grant from the National Natural
Science Foundation of China (No. 81171712), Jiangsu Province’s Key Provincial Tal-
ents Program (2011e15) and Jiangsu Province’s Key Medical Department in 2011.
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Introduction: Recently, recommendations were made for a bisphosphonate (BP)
“holiday” in patients using these drugs to minimise fragility fractures. BPs are
known to reduce fracture incidence and increase bone mass in osteoporotic
women. Based on the long half-life of BPs in bone (>5.5 yrs.), we hypothesised
that bone composition would not be altered by discontinuing BP for less than its
“half-life” in bone. BPs bind to mineral in bone with high affinity. Due to variable
turnover in different tissues and challenges of measurement, the precise “half-
life” or residence-time-in-bone for each BP remains debatable. Alendronate
(ALN) is reported to have a half-life 10 years.
Methods: To test this hypothesis, we acquired 30 trans-iliac-biopsies from a small
subgroup of 1099 patients, from the Fracture Intervention Trial (FIT) Long-term
Extension (FLEX) trial. FIT was a multi-centre, double-masked, placebo-controlled
trial, in which fracture incidence was documented in 6457 postmenopausal-women,
randomised to receive ALN or placebo. FLEX study participants, postmenopausal
women who had received ALN therapy (5 or 10 mg) for five years as part of the FIT
trial, were randomized to either continue receiving ALN for an additional five years
(Treatment group) or were switched to placebo (Discontinued group). Biopsies, ob-
tained at ten years were embedded in PMMA; 1-2 um sections of each were prepared
in triplicate and the cortical bone (from endosteal-periosteal surface) and intact
trabeculaewithin each biopsy were scanned (6.25 um spatial-resolution) on a Perkin
Elmer 300 Infrared Imaging System. These images provide spatially resolved maps of
tissue composition. Pixel distribution provides information about the tissue’s
compositional heterogeneity. Following data collection, subtraction of embedding
media, images were processed using ISYS 5.0 Software, mean and SD in each image
from cortical and cancellous bone was calculated for the variables: (i) mineral/ma-
trix ratio, (ii) carbonate/phosphate ratio, (iii) crystallinity, (iv) collagen maturity
and (v) acid phosphate substitution along with each of their respective heterogene-
ities. Comparisons between Discontinued and Treatment groups were made with an
unpaired t-test using Welch’s correction. Confidence limits (95%) are shown.
Results: Cortical and cancellous parameter means and heterogeneities of their dis-
tributions were not significantly different for all variables in the Discontinued and
Treatment groups. An exception was cancellous crystallinity heterogeneity which
was significantly increased (42%, PZ0.0368) for the Treatment group.
Discussion and Conclusions: Consistent lack of difference between Discontinued
and Treatment biopsies provides provisional support for our hypothesis. The
observed higher heterogeneity of cancellous crystallinity may reflect the existence
of some slightly larger-crystals in the presence of decreased remodelling. These
findings agree with previously reported similarity in clinical fracture-risk and
BMDD in these groups, suggesting that despite a reported difference in the amount
of bone lost, bone composition remained unaltered. Conclusions here are limited,
due to small sample size; power calculations suggest nZ60 would be needed to
detect significant differences. Additional studies with more patients and other
drugs are required to confirm our hypothesis.
http://dx.doi.org/10.1016/j.jot.2016.06.072134
THE PROMOTING EFFECTS OF SINUSOIDAL ELECTROMAGNETIC FIELDS ON
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Background: Electromagnetic fields have been reported to be able to improve
bone mineral density and are suggested to be a safe and non-invasive means for
treating osteoporosis or healing bone non-unions. However, the action mechanisms
and optimal application parameters remain unclear.
Subjects and Material: The rat calvarial osteoblasts were expanded in vitro and
exposed to 50 Hz 1.8 mT sinusoidal electromagnetic fields (SEMFs) for different
daily durations (0.5, 1, 1.5, 2, 2.5 or 3 h per day) for up to 12 days. The alkaline
phosphatase (ALP) activity, the colonies stained positive for ALP after 6 days and
the mineralized nodular formed after 12 days were measured, respectively. The
gene expression levels of Collagen type I, ALP, and BMP-2 were assayed by real-
time PCR. Eighty-four SD rats aged one month were randomly divided into six
groups and exposed to same SEMFs for 0 (used as control), 0.5, 1, 1.5, 2, 2.5
and 3 h per day, respectively. After two months, all rats were euthanized, and
the femurs and vertebrae were assayed by micro-CT scan, three-point bending
tests, and compression tests, as well as bone morphometrical analysis. The serum
osteocalcin levels and TRAP5b levels were measured with an ELISA method.
Results: It was found that compared to the non-treated control group, daily expo-
sure for 1.5 h produced the highest number and largest area of ALP+ CFU-F colonies
